Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Sanofi logo — A global integrated healthcare leader discovers, develops an...

Sanofi

A global integrated healthcare leader discovers, develops and distributes therapeutic solutions

Founded 1973 France France 93305 employees IPO Total: $8.67B

General Information

Company Name Sanofi
Founded Year 1973
Location France France +11
Employees 93305
Funding Stage IPO
Social

Get notified when Sanofi moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Sanofi is strategically advancing its therapeutic pipeline, evidenced by recent European regulatory approval for a subcutaneous multiple myeloma therapy, marking a significant step towards commercialization. Concurrently, the company is demonstrating a dual focus on global market development and social responsibility through the expansion of its community-focused programs across Africa and Asia. These developments, coupled with strategic partnerships and leadership recognition, underscore Sanofi's commitment to innovation and broader healthcare impact.

Signal Types
Regulatory Approval Expansion Partnership Product Development
Strategic Labels
Therapeutic Innovation Global Market Expansion Market Access
Next Move: Commercialization
·
Impact: 9/10
·
Ideal For: Global Biopharma Investors

About Sanofi

Sanofi, founded in 1973, is a global integrated healthcare leader headquartered in France. As an R&D driven, AI-powered biopharma company, it boasts a noteworthy focus on improving lives through therapeutic solutions.

The company leverages its deep expertise in the immune system to develop medicines and vaccines, addressing significant healthcare, environmental, and societal challenges. This focus positions Sanofi as a potential industry frontrunner with an innovative pipeline that could positively impact millions globally.

Sanofi recently secured a substantial $3.00 billion Post IPO Debt investment, indicating strong financial backing and confidence from the investment community. Investors eyeing opportunities in the integrated healthcare sector might find Sanofi a compelling option, given its strategic market positioning and ambitious growth trajectory.

Taxonomy: Integrated Healthcare, R&D Driven, AI-Powered Biopharma, Immune System Medicines, Therapeutic Solutions, Innovative Pipeline, Vaccines, Rare Diseases, Rare Blood Disorders, Neurology, Immunology, Oncology, Diabetes, Cardiovascular Diseases, Consumer Healthcare

Services & Products

Research & Development of Medicines and Vaccines
Clinical Trials Management
Digital Health Solutions
Manufacturing and Supply of Pharmaceuticals
Investor Relations and Business Development

Target Customers

Patients with Rare Diseases Healthcare Systems Medical Researchers Healthcare Providers Investors

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Debt •••••• - 01 Oct 2025
Post Ipo Debt •••••• - 01 Jun 2025
Post Ipo Debt •••••• 4
Investor Investor Investor
•••• •••• 		01 Mar 2025
Post Ipo Equity •••••• 1 •••• •••• 01 Mar 2022
Grant •••••• 1 •••• •••• 01 Jul 2020

View All 10 Funding Rounds

Latest News

View All
Düsseldorf Regional Court waits for validity judgments in CureVac v BioNTech — Juve-patent.com
Düsseldorf Regional Court waits for validity judgments in CureVac v BioNTech
Juve-patent.com Aug 17, 2023
Bay Area tech layoffs: Cancer screening company to cut 20% of workforce after securing $254 million — Sfchronicle.com
Bay Area tech layoffs: Cancer screening company to cut 20% of workforce after securing $254 million
Sfchronicle.com Apr 24, 2024
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more — Fiercebiotech.com
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more
Fiercebiotech.com Jan 13, 2025
Sanofi, Blueprint Medicines'ı 9,1 milyar dolara satın almaya hazırlanıyor — Webrazzi
Sanofi, Blueprint Medicines'ı 9,1 milyar dolara satın almaya hazırlanıyor
Webrazzi Jun 02, 2025
IA : Anthropic ouvre un bureau à Paris — Lesechos.fr
IA : Anthropic ouvre un bureau à Paris
Lesechos.fr Nov 07, 2025
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval — Cnbc
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
Cnbc Nov 23, 2025

Sanofi Alternatives & Competitors

View All Alternatives
Sanofi vs
Genomics England
Genomics England United Kingdom

We’re working to enable faster and deeper genomic diagnosis & research, to bring genomic healthcare...

556 employees
Biotechnology, Health Care
Compare Sanofi vs Genomics England
Sanofi vs
Novo Nordisk
Novo Nordisk Denmark

We’re here to champion long-term health. Get updates on innovation and inspiring stories 💙

IPO
62491 employees
Biotechnology, Pharmaceutical
Compare Sanofi vs Novo Nordisk
Sanofi vs
Sciensus
Sciensus United Kingdom

Sciensus is a life sciences business specialising in patient access, engagement and insight solution...

623 employees
Health Care
Compare Sanofi vs Sciensus
View all alternatives

FAQ About Sanofi

A global integrated healthcare leader discovers, develops and distributes therapeutic solutions
Sanofi was founded in 1973.
Sanofi is headquartered in France.
Sanofi has approximately 93305 employees.
Sanofi has completed 10 funding rounds, raising a total of $8.67B. The latest funding stage is IPO.
Sanofi offers: Research & Development of Medicines and Vaccines, Clinical Trials Management, Digital Health Solutions, Manufacturing and Supply of Pharmaceuticals, Investor Relations and Business Development.
Top alternatives and competitors to Sanofi include Genomics England, Novo Nordisk, Sciensus, ProQR Therapeutics, Oxalosis and Hyperoxaluria Foundation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sanofi and Genomics England are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Sanofi and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy